Reverse Mergers Gain Traction In Tough IPO Times
This article was originally published in Start Up
Executive Summary
Reverse mergers like Micromet's takeover of Cancervax and Cyclacel's takeover of Xcyte Therapies illustrate both tough times for IPO contenders as well as the innovative and sometimes win-win solution a reverse merger can provide.
You may also be interested in...
Infinity/Purdue: The Challenge of Reprising Roche/Genentech
Infinity's "Big Brother" deal with the privately held affiliates Purdue and Mundipharma comes closest of any recent deal to replicating the structure of the Genentech/Roche relationship -- swapping the majority of a biotech's pipeline to a well-heeled partner in return for independence from the capital markets and enough commercial upside to deliver a long-term return for investors. But the idiosyncrasies of the Purdue/Mundipharma ownership and structure, and the recent stormy history that opened minds to the possibility of such a deal, show why further iterations of the model will remain a rarity.
Infinity/Purdue: The Challenge of Reprising Roche/Genentech
Infinity's "Big Brother" deal with the privately held affiliates Purdue and Mundipharma comes closest of any recent deal to replicating the structure of the Genentech/Roche relationship -- swapping the majority of a biotech's pipeline to a well-heeled partner in return for independence from the capital markets and enough commercial upside to deliver a long-term return for investors. But the idiosyncrasies of the Purdue/Mundipharma ownership and structure, and the recent stormy history that opened minds to the possibility of such a deal, show why further iterations of the model will remain a rarity.
Sign Of The Times? Micromet’s Stock Price Sluggish Despite Reasons For Optimism
Biotech well-funded thanks to recent deals and sees blockbuster potential in lymphoma with blinatumomab.